LIM, SANG YONG,임상용,YOON, HYUN JIN,윤현진,KIM, DONG HO,김동호,LIM, SANG YONGKR,YOON, HYUN JINKR,KIM, DONG HOKR
申请号：
KR1020140164469
公开号：
KR1020160062289A
申请日:
2014.11.24
申请国别(地区):
KR
年份:
2016
代理人:
摘要：
According to the present invention, YC0843 (&Delta；STM2875, &Delta；relA/spoT), YC0844 (&Delta；STM3096, &Delta；relA/spoT), and YC0845 (&Delta；STM4332/4333, &Delta；relA/spoT) which are dual mutation genes have remarkably reduced viability in a normal organ, have a minimized negative effect caused by salmonella infection, and controls the size of tumor. Accordingly, it has been confirmed that the same may be useful as a pharmaceutical composition for treating cancer.본 발명의 이중 돌연변이 유전자인 YC0843(ΔSTM2875, ΔrelA/spoT), YC0844(ΔSTM3096, ΔrelA/spoT) 및 YC0845(ΔSTM4332/4333, ΔrelA/spoT)는 정상기관에서 생존력은 크게 감소하고 살모넬라 감염으로 인한 부정적인 효과를 최소화하면서 종양의 크기를 억제하여 암 치료용 약학적 조성물로 유용하게 활용될 수 있음을 확인하였다.
